|Bid||85.26 x 2200|
|Ask||85.29 x 900|
|Day's Range||85.04 - 86.27|
|52 Week Range||82.03 - 101.67|
|Beta (5Y Monthly)||0.46|
|PE Ratio (TTM)||30.06|
|Earnings Date||Sep. 27, 2021 - Oct. 01, 2021|
|Forward Dividend & Yield||1.36 (1.59%)|
|Ex-Dividend Date||Jul. 09, 2021|
|1y Target Est||91.17|
McCormick (MKC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Micron's (MU) Q4 results likely to reflect benefits from significant memory chip demand from data-center operators and PC manufacturers amid the pandemic-induced work-and-learn-from-home wave.
In a historically expensive market, with top stocks across a range of sectors competing for your attention, sometimes it's difficult to figure out which are the best companies for your investment portfolio. This is no small accomplishment, especially when you consider that the global pharmaceutical market was worth $1.3 trillion as of 2020, and is on track to reach a valuation of more than $1.7 trillion by the year 2025.